| 1. |
- Andersdotter, Amelia, et al.
(författare)
-
Godtyckligt regelverk hotar friheten på nätet
- 2013
-
Ingår i: Dagens Nyheter. - 1101-2447. ; :2013-09-03
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- Reglerna som möjliggör stängning av hemsidor på internet präglas av godtycke och otydlighet. Men det behöver inte vara särskilt svårt att skapa ett nytt och rättssäkert regelverk. Här har Sveriges EU-kommissionär Cecilia Malmström en viktig roll. Frågan är om hon tar sitt ansvar, skriver politiker och nätdebattörer.
|
|
| 2. |
- Björn van Praagh, Helena, et al.
(författare)
-
Metabolic fate of C-14-labelled chlorinated and non-chlorinated fatty acids in goldfish (Carassius auratus)
- 2004
-
Ingår i: Fish Physiology & Biochemistry. - : Springer Science and Business Media LLC. - 0920-1742 .- 1573-5168. ; 30:1, s. 13-20
-
Tidskriftsartikel (refereegranskat)abstract
- In order to study the metabolic fate of chlorinated fatty acids in fish, goldfish were fed either 9,10-dichlorostearic acid or oleic acid, chosen as the unchlorinated analogue, both radiolabelled at either the carboxyl (1st) or the terminal (18th) carbon of the fatty acid chain. By keeping the fish in hermetically closed aquaria, all the respired, assimilated and excreted radioactivity could be accounted for. Fish fed 9,10-dichlorostearic acid labelled in the terminal end respired radioactive CO2 to a much lower degree than fish fed the other test compounds. As a consequence, the radioactivity bound in lipids was higher in the group of fish fed dichlorostearic acid labelled in the terminal end. It is suggested that the chlorine atoms in the middle of the carbon chain obstruct the metabolic turn-over of 9,10-dichlorostearic acid, which may have an impact on the residence time of these compounds in the ecosystem.
|
|
| 3. |
- Mu, Huiling, et al.
(författare)
-
Fate of Chlorinated Fatty Acids in Migrating Sockeye Salmon and Their Transfer to Arctic Grayling
- 2004
-
Ingår i: Environmental Science & Technology. - : American Chemical Society (ACS). - 1520-5851 .- 0013-936X. ; 38:21, s. 5548-5554
-
Tidskriftsartikel (refereegranskat)abstract
- To investigate whether biotransport constitutes an entry route into pristine ecosystems for nonpersistent, nonvolatile xenobiotic compounds, extractable organically bound halogen in sockeye salmon (Oncorhynchus nerka) from Alaska was determined before and after spawning migration. The major organohalogen compounds in the salmon were halogenated fatty acids, predominantly chlorinated species that accounted for up to 35% of the extractable, organically bound chlorine (EOCl) in the fish tissues. The amount of chlorinated fatty acids in the salmon muscle decreased as a result of spawning migration. The decrease was correlated with that of triacylglycerols in the salmon muscle, indicating the chlorinated fatty acids to be mobilized and metabolized to approximately the same extent as the other fatty acids. Chlorinated fatty acids were also transferred to the maturing roe in a manner similar to that of the unchlorinated fatty acids. Lipids of the Arctic grayling (Thymallus arcticus), a fish resident to the spawning lake of the salmon, contained higher concentrations of chlorinated fatty acids than grayling in a lake without migratory salmon. This may reflect a food-chain transfer of the chlorinated fatty acids originating from the salmon, demonstrating a long-range transport route for this type of pollutants to pristine areas.
|
|
| 4. |
- Nilsson, Johan, et al.
(författare)
-
Paracetamol analogues conjugated by FAAH induce TRPV1-mediated antinociception without causing acute liver toxicity
- 2021
-
Ingår i: European Journal of Medicinal Chemistry. - : Elsevier BV. - 0223-5234 .- 1768-3254. ; 213
-
Tidskriftsartikel (refereegranskat)abstract
- Paracetamol, one of the most widely used pain-relieving drugs, is deacetylated to 4-aminophenol (4-AP) that undergoes fatty acid amide hydrolase (FAAH)-dependent biotransformation into N-arachidonoylphenolamine (AM404), which mediates TRPV1-dependent antinociception in the brain of rodents. However, paracetamol is also converted to the liver-toxic metabolite N-acetyl-p-benzoquinone imine already at therapeutic doses, urging for safer paracetamol analogues. Primary amine analogues with chemical structures similar to paracetamol were evaluated for their propensity to undergo FAAH-dependent N-arachidonoyl conjugation into TRPV1 activators both in vitro and in vivo in rodents. The antinociceptive and antipyretic activity of paracetamol and primary amine analogues was examined with regard to FAAH and TRPV1 as well as if these analogues produced acute liver toxicity. 5-Amino-2-methoxyphenol (2) and 5-aminoindazole (3) displayed efficient target protein interactions with a dose-dependent antinociceptive effect in the mice formalin test, which in the second phase was dependent on FAAH and TRPV1. No hepatotoxicity of the FAAH substrates transformed into TRPV1 activators was observed. While paracetamol attenuates pyrexia via inhibition of brain cyclooxygenase, its antinociceptive FAAH substrate 4-AP was not antipyretic, suggesting separate mechanisms for the antipyretic and antinociceptive effect of paracetamol. Furthermore, compound 3 reduced fever without a brain cyclooxygenase inhibitory action. The data support our view that analgesics and antipyretics without liver toxicity can be derived from paracetamol. Thus, research into the molecular actions of paracetamol could pave the way for the discovery of analgesics and antipyretics with a better benefit-to-risk ratio.
|
|
| 5. |
- Sagar, Rachel L, et al.
(författare)
-
An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol
- 2024
-
Ingår i: BMJ Open. - 2044-6055. ; 14:6
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction Severe osteogenesis imperfecta (OI) is a debilitating disease with no cure or sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile, show promising effects and can form bone. The Boost Brittle Bones Before Birth (BOOSTB4) trial evaluates administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells) for OI type 3 or severe type 4.Methods and analysis BOOSTB4 is an exploratory, open-label, multiple dose, phase I/II clinical trial evaluating safety and efficacy of postnatal (n=15) or prenatal and postnatal (n=3, originally n=15) administration of BOOST cells for the treatment of severe OI compared with a combination of historical (1–5/subject) and untreated prospective controls (≤30). Infants<18 months of age (originally<12 months) and singleton pregnant women whose fetus has severe OI with confirmed glycine substitution in COL1A1 or COL1A2 can be included in the trial.Each subject receives four intravenous doses of 3×106/kg BOOST cells at 4 month intervals, with 48 (doses 1–2) or 24 (doses 3–4) hours in-patient follow-up, primary follow-up at 6 and 12 months after the last dose and long-term follow-up yearly until 10 years after the first dose. Prenatal subjects receive the first dose via ultrasound-guided injection into the umbilical vein within the fetal liver (16+0 to 35+6 weeks), and three doses postnatally.The primary outcome measures are safety and tolerability of repeated BOOST cell administration. The secondary outcome measures are number of fractures from baseline to primary and long-term follow-up, growth, change in bone mineral density, clinical OI status and biochemical bone turnover.Ethics and dissemination The trial is approved by Competent Authorities in Sweden, the UK and the Netherlands (postnatal only). Results from the trial will be disseminated via CTIS, ClinicalTrials.gov and in scientific open-access scientific journals.Trial registration numbers EudraCT 2015-003699-60, EUCT: 2023-504593-38-00, NCT03706482.
|
|
